-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HBV-IN-13
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2724228-72-0.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2724228-72-0 |
| Description | HBV-IN-13 is a potent inhibitor of hepatitis B surface antigen (HBsAg). (Extracted from patent WO2021204252A1, compound 1_B) |
Product Information
| Synonyms | (S)-7-isopropyl-4-(3-methoxypropoxy)-11-oxo-6,11-dihydro-7H-[1,3]dioxolo[4,5-h]pyrido[2,1-a]isoquinoline-10-carboxylic acid |
| IUPAC Name | (7S)-4-(3-methoxypropoxy)-11-oxo-7-propan-2-yl-6,7-dihydro-[1,3]benzodioxolo[7,6-a]quinolizine-10-carboxylic acid |
| Molecular Weight | 415.44 |
| Molecular Formula | C22H25NO7 |
| Canonical SMILES | CC(C)C1CC2=CC(=C3C(=C2C4=CC(=O)C(=CN14)C(=O)O)OCO3)OCCCOC |
| InChI | InChI=1S/C22H25NO7/c1-12(2)15-7-13-8-18(28-6-4-5-27-3)20-21(30-11-29-20)19(13)16-9-17(24)14(22(25)26)10-23(15)16/h8-10,12,15H,4-7,11H2,1-3H3,(H,25,26)/t15-/m0/s1 |
| InChIKey | MGBFTHMYPGXZHP-HNNXBMFYSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 746 |
| Exact Mass | 415.16310214 |
| Target | HBV |
| XLogP3-AA | 3.6 |
